An effective vaccine strategy protective against antigenically distinct tumor variants

Kevin D. Pavelko, Karin L. Heckman, Michael J. Hansen, Larry R Pease

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antigenically distinct tumor variants can emerge in response to selective pressures inherent to host-tumor interactions. The development of successful immunotherapeutic strategies can be limited by these disparate antigenic profiles. Using the immunomodulator B7-DC XAb to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity of immune responses elicited by live tumors are distinct from the specificity of the responses elicited by soluble proteins derived from the same tumors. Remarkably, whereas the induced antitumor immunity generated against live variants of the B16 melanoma and EL4 thymic lymphoma tumors were highly specific for the original tumor variant used in the challenge, immunity generated using soluble proteins derived from tumor lysates was broadly reactive, recognizing the challenge tumor, as well as antigenically distinct variants. The antigens detected using live tumor and tumor lysate vaccines could be distinguished biochemically, demonstrating that they are structurally distinct. We show that vaccines using antigens present in tumor cell lysates induce protective immunity with strong memory against distantly related tumor variants. The existence of a class of antigens shared among tumor variants provides an attractive target for vaccine development.

Original languageEnglish (US)
Pages (from-to)2471-2478
Number of pages8
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Vaccines
Neoplasms
Immunity
Antigens
Thymus Neoplasms
Experimental Melanomas
Cancer Vaccines
Immunologic Factors
Neoplasm Antigens
Lymphoma
Proteins
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An effective vaccine strategy protective against antigenically distinct tumor variants. / Pavelko, Kevin D.; Heckman, Karin L.; Hansen, Michael J.; Pease, Larry R.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2471-2478.

Research output: Contribution to journalArticle

Pavelko, Kevin D. ; Heckman, Karin L. ; Hansen, Michael J. ; Pease, Larry R. / An effective vaccine strategy protective against antigenically distinct tumor variants. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2471-2478.
@article{94a70f3bfe62491ca1e009d28b3ec1cb,
title = "An effective vaccine strategy protective against antigenically distinct tumor variants",
abstract = "Antigenically distinct tumor variants can emerge in response to selective pressures inherent to host-tumor interactions. The development of successful immunotherapeutic strategies can be limited by these disparate antigenic profiles. Using the immunomodulator B7-DC XAb to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity of immune responses elicited by live tumors are distinct from the specificity of the responses elicited by soluble proteins derived from the same tumors. Remarkably, whereas the induced antitumor immunity generated against live variants of the B16 melanoma and EL4 thymic lymphoma tumors were highly specific for the original tumor variant used in the challenge, immunity generated using soluble proteins derived from tumor lysates was broadly reactive, recognizing the challenge tumor, as well as antigenically distinct variants. The antigens detected using live tumor and tumor lysate vaccines could be distinguished biochemically, demonstrating that they are structurally distinct. We show that vaccines using antigens present in tumor cell lysates induce protective immunity with strong memory against distantly related tumor variants. The existence of a class of antigens shared among tumor variants provides an attractive target for vaccine development.",
author = "Pavelko, {Kevin D.} and Heckman, {Karin L.} and Hansen, {Michael J.} and Pease, {Larry R}",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5937",
language = "English (US)",
volume = "68",
pages = "2471--2478",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - An effective vaccine strategy protective against antigenically distinct tumor variants

AU - Pavelko, Kevin D.

AU - Heckman, Karin L.

AU - Hansen, Michael J.

AU - Pease, Larry R

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Antigenically distinct tumor variants can emerge in response to selective pressures inherent to host-tumor interactions. The development of successful immunotherapeutic strategies can be limited by these disparate antigenic profiles. Using the immunomodulator B7-DC XAb to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity of immune responses elicited by live tumors are distinct from the specificity of the responses elicited by soluble proteins derived from the same tumors. Remarkably, whereas the induced antitumor immunity generated against live variants of the B16 melanoma and EL4 thymic lymphoma tumors were highly specific for the original tumor variant used in the challenge, immunity generated using soluble proteins derived from tumor lysates was broadly reactive, recognizing the challenge tumor, as well as antigenically distinct variants. The antigens detected using live tumor and tumor lysate vaccines could be distinguished biochemically, demonstrating that they are structurally distinct. We show that vaccines using antigens present in tumor cell lysates induce protective immunity with strong memory against distantly related tumor variants. The existence of a class of antigens shared among tumor variants provides an attractive target for vaccine development.

AB - Antigenically distinct tumor variants can emerge in response to selective pressures inherent to host-tumor interactions. The development of successful immunotherapeutic strategies can be limited by these disparate antigenic profiles. Using the immunomodulator B7-DC XAb to activate cytolytic T cells specific for tumor-associated antigens, we found that the specificity of immune responses elicited by live tumors are distinct from the specificity of the responses elicited by soluble proteins derived from the same tumors. Remarkably, whereas the induced antitumor immunity generated against live variants of the B16 melanoma and EL4 thymic lymphoma tumors were highly specific for the original tumor variant used in the challenge, immunity generated using soluble proteins derived from tumor lysates was broadly reactive, recognizing the challenge tumor, as well as antigenically distinct variants. The antigens detected using live tumor and tumor lysate vaccines could be distinguished biochemically, demonstrating that they are structurally distinct. We show that vaccines using antigens present in tumor cell lysates induce protective immunity with strong memory against distantly related tumor variants. The existence of a class of antigens shared among tumor variants provides an attractive target for vaccine development.

UR - http://www.scopus.com/inward/record.url?scp=42049107519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049107519&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5937

DO - 10.1158/0008-5472.CAN-07-5937

M3 - Article

C2 - 18381456

AN - SCOPUS:42049107519

VL - 68

SP - 2471

EP - 2478

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -